Abstract 341P
Background
Atezolizumab treatment provided significantly longer overall survival than pemetrexed/gemcitabine plus platinum based chemotherapy as a first-line treatment for stage IV non-small cell lung cancer (NSCLC) whose tumours have a high programmed death ligand 1 (PD-L1) expression as shown in the phase III IMpower110 trial. There is no study examining cost-effectiveness of atezolizumab monotherapy to inform policy making in Thailand.
Methods
A cost-effectiveness analysis used a partitioned survival model and was conducted from a payer perspective. Costs and outcomes of atezolizumab and gemcitabine plus platinum based chemotherapy, which is a standard of care in Thailand, were estimated over a 35-year time horizon. Clinical outcomes were derived from the IMpower110 trial assuming the clinical equivalence of gemcitabine and pemetrexed since pemetrexed was used for non-squamous population in the trial, however only gemcitabine is being used in Thailand. Costs were obtained from literature from the Thai setting. All outcomes and costs were discounted at 3% annually. Sensitivity analyses were performed to assess robustness of the results. The Thai willingness-to-pay threshold was set at $4,520/QALY.
Results
The atezolizumab treatment resulted in 3.78 life-years (LY) and 2.70 quality-adjusted life-years (QALY) gained at an additional cost of $44,770 compared with chemotherapy. The incremental cost-effectiveness ratio (ICER) were $11,841/LY and $16,553/QALY. Key factors influencing a change in ICER were discount rates for outcomes and costs.
Conclusions
Although atezolizumab has clinical benefits more than twice compared to standard chemotherapy, the ICER is still higher than the current threshold. To enhance patients’ access to this life-extending treatment at the end of life, alternative financing strategies and a concept of QALY shortfall could be considered to support policy decision-making.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
K. Kittrongsiri, S. Abogunrin, H. Celik, S. Sangroongruangsri: Financial Interests, Institutional, Full or part-time Employment: Roche.
Resources from the same session
354P - Decreased INPP5B expression predicts poor prognosis in lung adenocarcinoma
Presenter: jun deng
Session: Poster viewing 05.
355P - Anlotinib plus standard chemotherapy as first-line treatment in extensive-stage small cell lung cancer patients
Presenter: Wei Zhang
Session: Poster viewing 05.
356P - Efficacy and safety analysis of anlotinib and durvalumab plus chemotherapy in first-line therapy extensive-stage small cell lung cancer (SCLC)
Presenter: Lijuan Chen
Session: Poster viewing 05.
357P - Molecular stratification of small cell lung carcinoma subtypes by immunoexpression of ASCL1, NEUROD1, POU2F3 and YAP1 with clinicopathological correlation
Presenter: Sunil Pasricha
Session: Poster viewing 05.
358P - Intracranial metastatic disease (IMD) burden and management of patients with small cell lung cancer (SCLC): A population-based analysis of 8705 patients
Presenter: Karolina Gaebe
Session: Poster viewing 05.
359P - Epidermal growth factor receptor (EGFR) mutation testing and immunotherapy (IO) use associated with diagnosis of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins) in the US
Presenter: Sai-Hong Ou
Session: Poster viewing 05.
360P - ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib
Presenter: Zofia Piotrowska
Session: Poster viewing 05.
361P - 8-year long term survival status in a phase III randomized study in EGFR mutated advanced lung cancer patients in the first-line
Presenter: Ajaykumar Singh
Session: Poster viewing 05.
362P - Intracranial activity of dacomitinib in treatment naïve advanced EGFR mutated non-small cell lung cancer (NSCLC): Prespecified subgroup analysis of the ATORG-003 trial
Presenter: Aaron Tan
Session: Poster viewing 05.